Neurocrine Biosciences, Inc. (NBIX) Stock Price & How to Invest

Last updated November 2026

Short answer

You can invest in Neurocrine Biosciences (NBIX) by buying shares or fractional shares at any major broker, through an ETF that holds it, or as one holding in a thematic basket. Neurocrine is a profitable neuroscience biopharma whose tardive dyskinesia drug Ingrezza throws off real cash that funds a deepening psychiatry and neurology pipeline plus two newer launched products: Crenessity for congenital adrenal hyperplasia and Vykat XR for Prader-Willi syndrome, which came with the Soleno acquisition. The thesis is that this cash flow can diversify the company beyond one drug; the single biggest risk is that Ingrezza still drives the bulk of revenue and faces a Medicare negotiated price in 2029. As of October 16, 2026 the stock closed near $137 (market value ~$14 billion), down ~3% for the year.

NBIX stock price

As of 2026-11-16, Neurocrine Biosciences, Inc. (NBIX) last closed at $165.31, up 15.2% over the past year. Over the past 52 weeks it has traded between $123.10 and $185.50.

NBIX last close
$165.31
1 day
-1.25%
1 month
+21.81%
1 year
+15.15%
52-week range
$123.10 to $185.50
Last close
2026-11-16

Prices are daily closing prices from Yahoo Finance and may be delayed. For the live quote, check your broker or Neurocrine Biosciences, Inc.'s investor relations page. Walnut is informational, not investment advice.

NBIX key stats

At $165.31 on November 16, 2026, Neurocrine Biosciences, Inc. (NBIX) has a market cap of $16.7B and a P/E of 24.5 on trailing earnings (13.4 on forward earnings).

Market cap
$16.7B
P/E (trailing)
24.5
P/E (forward)
13.4
EPS (trailing 12 months)
$6.74
Price to book
4.3
Beta
0.33

Market cap, P/E and yield are measured at the $165.31 price on November 16, 2026, from Yahoo Finance figures pulled in November 2026. Earnings date from Yahoo Finance. Walnut is informational, not investment advice.

What's new with Neurocrine Biosciences, Inc. (NBIX)?

The last two weeks for Neurocrine Biosciences, Inc., as of November 17, 2026: the price move, the next earnings date, what the company filed with the SEC, and what analysts changed.

  • NBIX closed at $165.31 on November 16, 2026, down 2.1% over the past five trading days (from $168.86).
  • On November 4, 2026, Guggenheim raised its target to $224.00 from $207.00 (Buy).
  • On November 3, 2026, Morgan Stanley raised its target to $185.00 from $183.00 (Equal-Weight).
  • On November 3, 2026, RBC Capital raised its target to $190.00 from $187.00 (Outperform).

Neurocrine Biosciences, Inc. filed no current, quarterly or annual report with the SEC in the last two weeks.

Prices are daily closes from Yahoo Finance. Filings are read from SEC EDGAR every six hours. Analyst actions come from Yahoo Finance as of November 2026. Walnut is informational, not investment advice.

Neurocrine Biosciences, Inc. (NBIX) latest quarter

Neurocrine Biosciences reported revenue of $1.1 billion for Q3 2026, up 41% from a year earlier (Neurocrine Biosciences, Nov 2, 2026).

Revenue
$1.1 billion
up 41% from a year earlier
Diluted EPS (GAAP)
$1.96
down 4% from a year earlier
INGREZZA
$802 million
up 17% from a year earlier

Source: Neurocrine Biosciences Q3 2026 results, Nov 2, 2026. Full earnings breakdown

What does Neurocrine Biosciences, Inc. (NBIX) do?

Neurocrine Biosciences makes money primarily from Ingrezza (valbenazine), an oral VMAT2 inhibitor for tardive dyskinesia and chorea associated with Huntington's disease. Ingrezza generated about $657 million in net product sales in Q1 2026, up roughly 20 percent year over year, and in September 2026 management cited raised full-year 2026 guidance of about $2.825 to $2.875 billion. A second product, Crenessity (crinecerfont), launched for classic congenital adrenal hyperplasia and had reached an annualized revenue run rate of about $750 million six quarters into its launch. A third, Vykat XR (diazoxide choline) for hyperphagia in Prader-Willi syndrome, arrived with the roughly $2.9 billion Soleno Therapeutics acquisition and runs at about $400 million annualized. Total revenue rose to ~$959 million in the June 2026 quarter, up ~40% year over year, and trailing-twelve-month revenue reached ~$3.37 billion with net income of ~$706 million.

Founded in 1992 and based in San Diego, Neurocrine spent years as a clinical-stage company before Ingrezza's 2017 approval turned it into a commercial neuroscience franchise. It has since built a pipeline spanning psychiatry and neurology, headlined by direclidine (NBI-1117568), a selective muscarinic M4 agonist for schizophrenia that produced positive Phase 2 data and has entered a Phase 3 registrational program, and osavampator, an AMPA potentiator in three Phase 3 depression trials with data expected in the second half of 2027. Additional muscarinic compounds licensed from Nxera Pharma and an early once-weekly CRF2 agonist for obesity round out the bets. In September 2026 the company named Eiry Roberts, M.D., as Chief Medical Officer.

What's driving Neurocrine Biosciences, Inc. (NBIX)?

Ingrezza is a durable, growing cash engine

Ingrezza net sales reached about $657 million in Q1 2026, up roughly 20 percent year over year on double-digit growth in new patient additions, and by September 2026 management had lifted full-year 2026 guidance to about $2.825 to $2.875 billion. Patent protection runs through 2038, and the company expects double-digit volume growth in 2027-2028 within a roughly 100,000-patient VMAT2-treated population. The longer-term cap is Medicare: Ingrezza's negotiated maximum fair price takes effect in 2029, when management expects revenue to decline.

Crenessity adds a real second product

Crenessity, the first non-glucocorticoid therapy for classic congenital adrenal hyperplasia, contributed about $153 million in Q1 2026 and had reached an annualized run rate near $750 million by September 2026, a fast ramp for a recent launch. Two-year data presented in 2026 showed sustained glucocorticoid dose reductions while maintaining hormone control, and in October 2026 Neurocrine presented real-world evidence on the lifelong impact of the disease. A genuine second franchise reduces reliance on a single drug.

Deep central nervous system pipeline

Neurocrine's pipeline spans psychiatry and neurology, led by direclidine (NBI-1117568), a selective muscarinic M4 agonist that posted statistically significant Phase 2 schizophrenia data and entered a Phase 3 registrational program, with bipolar mania also in development. Osavampator is in three replicate Phase 3 depression trials, with data expected in the second half of 2027 and a possible launch in 2029 if positive. Additional muscarinic compounds licensed from Nxera Pharma broaden the bet. Success in schizophrenia or depression would open large new markets beyond movement disorders.

Profitable and self-funding

Unlike many biotechs, Neurocrine is consistently profitable, with trailing-twelve-month net income of ~$706 million on ~$3.37 billion of revenue, an operating margin near 22%, and free cash flow of ~$638 million as of mid-2026. That profitability let it fund the roughly $2.9 billion Soleno deal and late-stage trials without depending on dilutive financing, though cash on hand fell to ~$390 million against ~$462 million of debt afterward.

Vykat XR adds a rare-disease franchise

The Soleno acquisition brought Vykat XR, a treatment for hyperphagia in Prader-Willi syndrome, which management described in September 2026 as running at about $400 million annualized with more than 1,400 patient-years of experience. RBC said in October 2026 that it expects Vykat XR sales to stay roughly flat in the near term, and discontinuation of 20-25% over about a year, plus an August statement on deaths and adverse events, are points investors are watching.

What are the risks to Neurocrine Biosciences, Inc. (NBIX)?

The dominant risk is concentration: Ingrezza still drives the majority of revenue, so any erosion from VMAT2 competition, formulary or payer pressure, or pricing reform would hit results disproportionately. That reform is already scheduled: Ingrezza's Medicare negotiated price takes effect in 2029, management expects revenue to decline that year, and rival Austedo reaches its negotiated price two years earlier, in 2027. CNS drug development is also high-risk, and a single Phase 3 miss for the muscarinic or depression programs could sharply reset expectations. The Soleno acquisition adds integration and execution risk, with Vykat XR sales expected to be flat near term and safety reports under scrutiny, and the deal cut the cash balance to ~$390 million. The stock can be volatile around trial readouts, label decisions, and guidance updates; it fell ~24% over the three months to mid-October 2026.

What is the Neurocrine Biosciences, Inc. (NBIX) forecast?

28 analysts publish price targets on NBIX, averaging $208.11 as of November 2026, or +25.9% against the $165.31 share price on November 16, 2026. The published targets run from $150.00 to $253.00, a moderate spread, and the ratings split 24 buy, 4 hold, 0 sell. Over the last six months there have been 7 raises and 3 cuts among the published actions. A price target is what an analyst published on a date, not a prediction, and sell-side ratings skew positive across the whole market.

Read the full NBIX forecast and price target for the target table, the recent rating actions by firm, and how the consensus has shifted.

Is NBIX a buy or a sell?

We give no verdict on Neurocrine Biosciences, Inc.. Both cases are real, which is why the question is contested at all, so here is the strongest version of each.

The case for buying. Ingrezza is a durable, growing cash engine. Ingrezza net sales reached about $657 million in Q1 2026, up roughly 20 percent year over year on double-digit growth in new patient additions, and by September 2026 management had lifted full-year 2026 guidance to about $2.825 to $2.875 billion. The most optimistic published target, $253.00, assumes this works close to its best case.

The case against. The dominant risk is concentration: Ingrezza still drives the majority of revenue, so any erosion from VMAT2 competition, formulary or payer pressure, or pricing reform would hit results disproportionately. The most pessimistic target, $150.00, is roughly what NBIX is worth if this bites instead.

Read the full bull and bear case on NBIX, including what would have to change to break either one. Walnut is not an investment adviser.

Has Neurocrine Biosciences, Inc. (NBIX) split its stock?

No. Neurocrine Biosciences, Inc. (NBIX) has not split its stock in the last 10 years. The statement covers only the window we check, so an older split in the company’s history is possible. It also matters less than it once did: fractional shares mean a high price per share no longer keeps smaller investors out, which removed most of the practical reason to split.

How is Neurocrine Biosciences, Inc. (NBIX) valued?

Market cap, P/E and dividend yield at today's price are in the NBIX key stats above. The business figures below come from Neurocrine Biosciences, Inc.'s reported results as of October 2026 and change when it next reports.

  • Revenue (TTM): ~$3.37 billion
  • Revenue growth: ~40% year over year in Q2 2026 (~$959 million)
  • Ingrezza 2026 guidance: ~$2.825-2.875 billion
  • Margins: Gross ~64%; operating ~22%; net ~21%
  • Net income (TTM): ~$706 million (EPS ~$6.82)

As of October 2026: Neurocrine trades near 20 times trailing and about 11 times forward earnings, a lower multiple than in mid-2026 after the shares fell ~24% over three months, as investors price in the 2029 Medicare cut to Ingrezza and the Soleno deal's execution. Third-quarter results are due November 2, 2026, with consensus near ~$1.04 billion of revenue and EPS of ~$2.72; the 29 analysts covering it average a strong-buy rating with a mean target near $207.

What themes does Neurocrine Biosciences, Inc. (NBIX) fit?

These are the investment theses NBIX naturally fits into. Each links to a full theme guide listing every other stock that belongs and the ETFs commonly used as a passive proxy.

Who competes with Neurocrine Biosciences, Inc. (NBIX)?

Tardive dyskinesia / VMAT2 inhibitors

Ingrezza's most direct competitor is Teva's Austedo (deutetrabenazine), the other branded VMAT2 inhibitor for tardive dyskinesia. Generic tetrabenazine also exists. This category is where Ingrezza concentration risk is most visible, since both products target overlapping prescriber bases and payer formularies.

Central nervous system biopharma

In psychiatry and neurology, Neurocrine competes for pipeline leadership and prescribers with companies such as Sage Therapeutics, Axsome Therapeutics, Intra-Cellular (now part of Johnson & Johnson), and Acadia Pharmaceuticals, particularly as it pushes into schizophrenia and depression.

Large diversified pharma

Broader neuroscience and rare-disease ambitions put Neurocrine alongside large players like AbbVie, Johnson & Johnson, and Bristol Myers Squibb, which have deep CNS franchises, larger sales forces, and the balance sheets to compete on commercialization and dealmaking.

What stocks are similar to Neurocrine Biosciences, Inc. (NBIX)?

Other names that sit close to NBIX: same theme, named as a direct competitor, or held beside it in the same funds. Each entry says which. They are useful if you want to spread one thesis across several tickers.

How to invest in Neurocrine Biosciences, Inc. (NBIX)

There are three common ways to get NBIX exposure. Buy shares (or fractional shares) directly at any major broker. Hold an ETF that includes it, which spreads the position across many companies. Or build it into a focused thematic portfolio, so NBIX sits alongside other stocks that express the same thesis.

Walnut takes the portfolio route. Describe a thesis where NBIX fits (for example “AI infrastructure” or “dividend-growth large-caps”) and the AI proposes 5 to 6 constituents with target weights. You review the plan and fund it through your own broker when you're ready.

New to this? Start with how to invest in stocks, see how to analyze a stock with AI, or compare the best AI stock analyzers.

The bottom line on Neurocrine Biosciences, Inc. (NBIX)

Neurocrine today is a commercial-stage neuroscience company built around Ingrezza, which carries raised full-year 2026 guidance of about $2.825 to $2.875 billion, alongside a fast-ramping Crenessity (about a $750 million annualized run rate by September 2026), Vykat XR (about $400 million annualized) and a central nervous system pipeline led by Phase 3 programs in depression and schizophrenia. Total revenue reached ~$959 million in the June 2026 quarter, up ~40% from a year earlier, yet the shares have slipped ~3% in 2026 and trade near 11 times forward earnings as investors weigh the 2029 Ingrezza price cut. If you believe a single profitable franchise can fund genuine diversification into psychiatry and neurology, the question becomes sizing and overlap with biotech and healthcare you already own, not timing. The risk is concentration: most revenue still comes from one drug, and pipeline readouts in CNS are binary, so a single trial miss or new competitor can move the stock sharply.

More on Neurocrine Biosciences, Inc. (NBIX)

Whether NBIX is worth buying today depends more on your time horizon and what you already hold than on any single call. We walk through valuation, what would have to go right, and the risks in is NBIX a buy or a sell?, and where the stock could go from here in the NBIX stock forecast.

For income investors, whether NBIX pays a dividend and how the payout looks is covered in does NBIX pay a dividend? And to weigh NBIX against a peer, read the full side-by-side comparisons: NBIX vs VRTX and NBIX vs REGN.

Wondering how NBIX fits the portfolio you already own? Walnut is an AI investing app that connects your brokerage read-only and answers questions like that about your actual holdings: overlap, concentration, and how each position tracks the S&P 500. Compare the best AI portfolio analyzers or see the best AI investing apps in 2026.

Your questions about Neurocrine Biosciences, Inc.

Ask Walnut's AI anything about NBIX and see how it fits what you own.

FAQ

Is NBIX a good stock to buy right now?

+

That depends on your goals, time horizon, and risk tolerance, and this is not investment advice. The bull case is a profitable, cash-generating Ingrezza franchise funding a deep CNS pipeline, plus two newer products in Crenessity and Vykat XR, at about 11 times forward earnings as of October 2026. The bear case is heavy reliance on one drug that faces a Medicare negotiated price in 2029, plus binary trial risk. Weigh how it fits your overall portfolio rather than timing a single entry.

What does Neurocrine do?

+

Neurocrine Biosciences is a San Diego neuroscience biopharmaceutical company that develops and sells treatments for neurological, neuroendocrine, and psychiatric conditions. Its commercial products include Ingrezza for tardive dyskinesia, Crenessity for congenital adrenal hyperplasia, and Vykat XR for Prader-Willi syndrome, and it runs a pipeline spanning schizophrenia, depression, and other central nervous system disorders.

What is Ingrezza?

+

Ingrezza (valbenazine) is Neurocrine's flagship product, an oral VMAT2 inhibitor approved for tardive dyskinesia and for chorea associated with Huntington's disease. It is the company's largest revenue source, with about $657 million in net sales in Q1 2026 and full-year 2026 guidance raised to roughly $2.825 to $2.875 billion. Its Medicare negotiated price takes effect in 2029.

Does NBIX pay a dividend?

+

Neurocrine Biosciences does not currently pay a dividend. Like many growth-oriented biopharma companies, it reinvests profits into research, late-stage clinical trials, commercialization, and acquisitions such as the roughly $2.9 billion Soleno deal. Investors in NBIX are generally seeking potential share-price appreciation rather than dividend income.

What is Crenessity?

+

Crenessity (crinecerfont) is Neurocrine's second commercial product, an oral CRF1 receptor antagonist for classic congenital adrenal hyperplasia. It offers a non-glucocorticoid mechanism to control excess hormones and reduce steroid exposure. It contributed about $153 million in Q1 2026 net sales and reached an annualized run rate of about $750 million by September 2026, six quarters into launch.

Why is Ingrezza concentration a risk for NBIX?

+

Ingrezza still accounts for the large majority of Neurocrine's revenue, so the company's results are tightly linked to one product. New competition, such as Teva's Austedo, formulary or payer pressure, pricing reform, or any safety or label change could disproportionately affect total revenue until Crenessity and the pipeline carry more weight.

How can I invest in NBIX through an ETF?

+

Neurocrine is a component of many biotech and healthcare ETFs, including broad biotech index funds and pharmaceutical sector funds. Buying such an ETF gives you exposure to NBIX alongside dozens of other biopharma names, which spreads out single-stock and pipeline risk. Check any fund's holdings to confirm its weight in Neurocrine.

What could move NBIX stock in 2026 and beyond?

+

The next catalyst is third-quarter results on November 2, 2026 (consensus ~$1.04 billion of revenue and EPS of ~$2.72). Beyond that: Ingrezza sales versus raised guidance, the Crenessity and Vykat XR trajectories, Phase 3 progress for direclidine in schizophrenia, osavampator depression data expected in the second half of 2027, and how the 2029 Medicare price for Ingrezza plays out. Many of these events are binary, which adds volatility.

How did Neurocrine do in its latest quarter?

+

In the June 2026 quarter Neurocrine reported revenue of ~$959 million, up ~40% from a year earlier and up from ~$815 million in March, helped by Crenessity and the newly added Vykat XR. EPS of $2.85 beat the ~$1.96 consensus, though net income of ~$144 million was lower than the prior quarter's ~$198 million. The next report is due November 2, 2026.

How has NBIX stock performed in 2026?

+

As of the October 16, 2026 close near $137, NBIX was down ~3% year to date and roughly flat (~-1%) over one year, after falling ~24% over the prior three months. Its 52-week range runs from ~$122 to ~$186. In September 2026 RBC cut its price target to $187 from $198 while keeping an outperform rating.

Guides that feature NBIX

NBIX is one of the names covered in these guides. Each one puts the stock next to its peers so you can see where it fits rather than judging it alone.

Walnut is informational, not investment advice. Financial figures on this page are approximations; always verify current numbers with Neurocrine Biosciences, Inc.'s investor relations page or your broker before making investment decisions.